Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Ovarian Neoplasms 10Breast Neoplasms 6Triple Negative Breast Neoplasms 3Sarcoma 3Fallopian Tube Neoplasms 3Prostatic Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Breast Cancer Metastatic 2Small Cell Lung Carcinoma 1Sarcoma, Ewing 1SCLC, Extensive Stage 1Recurrence 1Platinum-sensitive Relapsed Ovarian Cancer 1Osteosarcoma 1Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Kenny-Caffey syndrome, Type 1 1Her-2 Negative Breast Cancer 1Glioblastoma 1Fludzoparib" and Anti-angiogenic 1Female Breast Cancer Patients 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

Fulvestrant 5dalpiciclib 3Letrozole 3ribociclib 2palbociclib 2fluzoparib 2exemestane 2apatinib 2Anastrozole 2trastuzumab deruxtecan 1sacituzumab govitecan 1pyrotinib 1pegfilgrastim 1patritumab deruxtecan 1olaparib 1irinotecan sucrosofate 1abemaciclib 1Zoledronic Acid 1Rogaratinib 1Patient Reported Outcome Measures 1Paclitaxel 1Neoadjuvant Therapy 1Liposomes 1Irinotecan 1Ga(III)-DOTATOC 1Everolimus 1Cell Separation 1Capecitabine 1Bevacizumab 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Breast Cancer Metastatic × fluzoparib × Clear all
NCT06612814 2024-09-25

PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Fudan University

Phase 3 Active not recruiting
307 enrolled
Breast

Breast Cancer Metastatic

NCT05759546 2024-02-06

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Fudan University

Phase 2 Recruiting
200 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡